Učitavanje...
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
BACKGROUND: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and t...
Spremljeno u:
| Izdano u: | Diabetes Metab Syndr Obes |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4541559/ https://ncbi.nlm.nih.gov/pubmed/26316788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S34418 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|